PF-06671008 Dose Escalation Study in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 28, 2016

Primary Completion Date

March 29, 2019

Study Completion Date

March 29, 2019

Conditions
Neoplasms
Interventions
DRUG

PF-06671008

Dose Escalation Phase - Part 1

DRUG

PF-06671008

Dose Expansion Phase - Part 2

Trial Locations (9)

10017

Memorial Sloan Kettering Cancer Center- Clinical Trials Office, New York

10022

Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Cancer Center - Westchester, Harrison

44106

University Hospitals Cleveland Medical Center, Cleveland

77030

The University of Texas - M.D. Anderson Cancer Center, Houston

The University of Texas MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Hospital, Salt Lake City

Huntsman Cancer Institute, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02659631 - PF-06671008 Dose Escalation Study in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter